key: cord-1035463-9t4rqykw
authors: Nakagami, Hironori
title: Development of COVID-19 vaccines utilizing gene therapy technology
date: 2021-03-27
journal: Int Immunol
DOI: 10.1093/intimm/dxab013
sha: 25fbb4033c738986515584261416ce6f2e3755cf
doc_id: 1035463
cord_uid: 9t4rqykw

There is currently an outbreak of respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) is caused by infection with SARS-CoV-2. Individuals with COVID-19 have symptoms that are usually asymptomatic or mild in most initial cases. However, in some cases, moderate and severe symptoms have been observed with pneumonia. Many companies are developing COVID-19 vaccine candidates using different technologies that are classified into four groups (intact target viruses, proteins, viral vectors and nucleic acids). For rapid development, RNA vaccines and adenovirus vector vaccines have been urgently approved, and their injection has already started across the world. These types of vaccine technologies have been developed over more than 20 years using translational research for use against cancer or diseases caused by genetic disorders but the COVID-19 vaccines are the first licensed drugs to prevent infectious diseases using RNA vaccine technology. Although these vaccines are highly effective in preventing COVID-19 for a short period, safety and efficiency evaluations should be continuously monitored over a long time period. As the time of writing, more than 10 projects are now in phase 3 to evaluate the prevention of infection in double-blind studies. Hopefully, several projects may be approved to ensure high-efficiency and safe vaccines.

There is currently an outbreak of respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 is caused by infection with SARS-CoV-2. To combat the worldwide COVID-19 pandemic, the development of effective and safe vaccines against SARS-CoV-2 is urgently required. Many pharmaceutical companies and researchers are developing vaccines against SARS-CoV-2, including vaccines based on inactivated target virus or viral proteins, adenovirus vectors and RNA/DNA from SARS-CoV-2 (1) (2) (3) (4) (5) . The target antigen is the spike glycoprotein of SARS-CoV-2 or its receptor-binding domain (RBD), which is essential for virus entry into cells (6) .

The vaccines are classified into four groups based on the vaccine technology.

Intact target virus vaccines include inactivated and attenuated viruses, which are common as preventive vaccines for infectious diseases. Basically, this type of vaccine exposes the body to viruses that do not cause disease but induce an efficient immune response that can inhibit viral infection. These viruses are manufactured through passage in human cells or animals, which may cause favorable mutations for use in weakened or inactivated vaccines. Recently, it has become possible to alter the genetic code to make favorable mutations for weakened or inactivated vaccines. A Chinese company has rapidly developed an inactivated-virus vaccine for SARS-CoV-2 (7) and performed phase 3 clinical trials. They announced that the vaccine had an efficiency of 79% (not yet published), and it has been approved in China and the United Arab Emirates. An Indian company also rapidly developed an inactivated-virus (2) Protein-based vaccines This type of vaccine includes whole proteins, a fragment of a protein or an outer shell that mimics the coronavirus, such as virus-like particles (VLPs). This approach tries to synthesize only the necessary part of the protein as an antigen, such as spike glycoprotein or its RBD. Importantly, this vaccine type may require the co-administration of adjuvants to stimulate innate immunity, leading to the activation of an efficient acquired immune response. Novavax has reported having promising results in phase 1/2 clinical trials using recombinant protein and adjuvants (9) . Their vaccine, NVX-CoV2373, is a recombinant nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and adjuvant.

VLPs may induce a strong immune response without infectious risk because they mimic only the shell of the coronavirus structure. However, VLPs are usually difficult to manufacture, especially at a clinical grade on a large scale.

Viral vectors are tools to efficiently deliver genetic material into cells. As viral vectors, viruses are genetically engineered to efficiently produce some coronavirus proteins. Measles or adenovirus have been utilized as vectors that can efficiently enter cells, but the viral vector itself is weakened and cannot cause disease. This type of viral vector has achieved high transfection efficiency and has been developed over more than 20 years, using translational A c c e p t e d M a n u s c r i p t 5 research on gene therapy, as an efficient therapy for cancer or diseases caused by genetic disorders. Recently, an Ebola vaccine using virus vectors has been approved based on a clinical trial (10) (11) (12) (13) , which is the first approved viral vector vaccine drug for infectious disease.

In the challenge of rapid vaccine development for COVID-19, an adenovirus vector has been utilized, which is a nonreplicating viral vector. Because the adenovirus vector is strongly immunogenic, a situation in which the immune system could learn to recognize the viral vector as a foreign object that needs to be destroyed must be avoided. Therefore, researchers at Oxford University, with AstraZeneca, developed a vaccine by genetically engineering an adenovirus that normally infects chimpanzees. Early in the pandemic, they started a phase 1/2 trial. The results showed no severe side effects in the trial, but antibodies against the coronavirus were induced, as well as other immune defenses (14) . In the immunogenicity data, the SARS-CoV-2 neutralizing-antibody titer (ID50 shown in GMT; geometric mean titer) was increased in both low dose (2.2 x 10 10 viral particles) and standard dose (5 x 10 10 particles) and there is no difference at different ages (Table 1) . Their group began phase 2/3 trials in the United Kingdom (UK) and India and later launched phase 3 trials in Brazil, South Africa, and the United States of America (USA) ( Table 2 ).

The Oxford University / AstraZeneca clinical trial was halted to investigate a volunteer who developed transverse myelitis. Within one week, the trial began again after the judgment of the safety evaluation committee. In a study of the first 131 cases of in trials in the UK and Brazil, the vaccine had good efficacy. Although the volunteers all received two doses, an initial half-strength dose and second standard-dose shots led to 90% efficacy, whereas two standard-dose shots led to 60.3% efficacy in UK and 64.2% efficacy in Brazil (15) . This vaccine has been approved for emergency use in the UK, Argentina, A c c e p t e d M a n u s c r i p t 6 Australia, the European Union, India, South Korea, Thailand etc. and the World Health Organization gave approval as an emergency use listing.

Researchers at the Beth Israel Deaconess Medical Center / Johnson and Johnson also utilized adenovirus 26 (Ad26) for a COVID-19 vaccine. They started a phase 1/2 trial in July 2020. The study design was to administer the Ad26.CoV2.S vaccine at a dose of 5 x 10 10 particles (low dose) or 1 x 10 11 particles (high dose) in a single-dose or two-dose regimen.

The results showed no severe side effects in the trial (16) . As shown in Table 1 , the neutralizing antibody titer was increased at day 57 after the first vaccine dose (GMT; 288 to 488) for both the low dose (5 x 10 10 viral particles) and the high dose (1 x 10 11 particles). A second dose provided a further increase in the neutralizing antibody titer (GMT; 827 to 1266). On the basis of these results, they launched a phase 3 trials using one dose rather than two in USA, South Africa and Brazil. This single shot vaccine led to 62.1% efficacy in total, 72.0% efficacy in the USA, 64.0% efficacy in South Africa and 68.1% in Brazil. There is no difference across ages (66.1% for patients at 18-59 years old and 66.2% for those ≥60 years old). This vaccine has been approved as for emergency use in the USA, Canada and Bahrain.

Other projects using adenovirus vectors have also currently moved to phase 3 clinical trials, and some vaccines have been rapidly approved in China and Russia. In China, an early-stage trial was quickly conducted using recombinant adenovirus type-5 (Ad5). One hundred and eight participants received a single dose of the vaccine that induced an immune response within two weeks (17) . In phase 2,508 participants were randomly assigned to receive the vaccine (low dose or high dose) or placebo. Both doses of the vaccine induced significant neutralizing antibody responses and T cell activation (18) . On the basis of these results, the Chinese military approved the vaccine on June 25 in 2020 as a specially needed drug. This vaccine has also been approved for emergency use in Mexico and Pakistan.

A c c e p t e d M a n u s c r i p t 7 In Russia, a combination vaccine of two adenoviruses, Ad5 and Ad26, has been developed. In the phase 1 and 2 studies, nine volunteers received Ad26 in phase 1, nine received Ad5 in phase 1, and 20 received Ad26 and Ad5 in phase 2. The heterologous Ad26 and Ad5 vector-based COVID-19 vaccine has a good safety profile and induces humoral and cellular immune responses in participants (19) . In the preliminary evidence based on their phase 3 trial, the vaccine demonstrated more than 90% efficacy with no serious side effects

(not yet published). This vaccine has been approved for emergency use in the Argentina, Bahrain, Egypt, Mexico, Vietnam etc. Surprisingly, it has been combined with another adenovirus vector vaccine produced by AstraZeneca. The two teams will evaluate their vaccines to see if the mixture can increase the efficacy of the AstraZeneca vaccine. A c c e p t e d M a n u s c r i p t 8 BioNTech and Pfizer presented the initial results of clinical trials very rapidly (20, 21) (Table 3) . Initially, they designed two types of lipid nanoparticle-formulated RNA vaccine candidates: BNT162b1, which encodes a secreted trimerized SARS-CoV-2 RBD, and BNT162b2, which encodes a prefusion stabilized membrane-anchored SARS-CoV-2 fulllength spike. In both younger and older adults, the two vaccine candidates elicited similar dose-dependent SARS-CoV-2-neutralizing antibody titers. BNT162b2 was associated with less systemic reactogenicity, particularly in older adults.

These results supported selection of the BNT162b2 vaccine candidate for phase 2/3 large-scale safety and efficacy evaluation (21) . In the phase 3 clinical trial, a total of 43,448 participants received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of COVID-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to receive the placebo;

BNT162b2 was thus 95% effective in preventing COVID-19 (22) . The Although these RNA vaccines are highly effective in preventing COVID-19 in the short term, safety and efficiency evaluations should be continuously monitored for a long time period.

In terms of DNA vaccines, several projects have been conducted for COVID-19

vaccines, but no DNA-based vaccines have been approved up to now. DNA vaccines can be delivered intramuscularly or intradermaly, which primarily induces the expression of antigen in myocytes or keratinocytes, respectively, but also in antigen-presenting cells near the injection side (26) (27) (28) (29) (30) . Thus, DNA vaccines can theoretically activate cellular immunity as well as the humoral immunity, and be stable, cost-efficient, easy to manufacture and safe to handle.

In the history of DNA vaccines, the first clinical trial was started in the 1990s and more than a hundred clinical trials that focus on DNA vaccination have been registered.

There are no approved DNA vaccines for use in humans up to now. Nevertheless, some DNA-based vaccines were approved for veterinary use, including a vaccine against West Nile virus in horses (31) and canine melanoma (32) . In the first human clinical trials, a DNA vaccine against HIV showed a potential, but not significant, immunogenicity (33) . A malaria-

A c c e p t e d M a n u s c r i p t 10 plasmid encoding different antigens (34) . A DNA vaccine for hepatitis B virus showed the induction of a humoral response in patients (35) . However, in most cases, the level of the immune response most was not sufficient to elicit significant clinical benefits. The unsolved issue is the low immunogenicity of DNA vaccines in humans, probably because of the low amount of administered plasmid DNA. To overcome this issue, the delivery and transfection system has been optimized over many years (36) . Actually, jet injectors (37), liposomes (38, 39) and electroporation (40) have enhanced responses through an increased efficiency of DNA delivery and have been recently utilized in clinical trials.

In the challenge of plasmid DNA vaccines for COVID-19, INOVIO developed a DNA vaccine that is delivered into the skin by electroporation. In a phase 1 trial, they confirmed a humoral and cellular immune response without serious adverse effects (41) .

Zudus in India also developed a plasmid DNA vaccine that is delivered into the skin by injectors. They have completed a Phase 2 trial and started phase 3 trials. We also developed a plasmid DNA vaccine that is delivered into muscle by a needle injection or into the skin by a novel pyro-drive jet injector in a phase 1/2 trial. This delivery system may possibly enable precise targeting with effective gene expression intradermally, which will hopefully overcome the remaining issue in the translational research of DNA vaccines in future years. 

At the time of writing, more than 10 projects are now in phase 3 to evaluate the prevention of infection in double-blind studies. A few vaccines have been approved for full use, and several vaccines have been approved for early or limited use in the world. Hopefully, several projects may be fully approved as high-efficiency and safe vaccines.

This study was supported by a Project Promoting Support for Drug Discovery grant M a n u s c r i p t 18 

SARS-CoV2 mRNA vaccine design enabled by prototype pathogen preparedness

SARS-CoV-2 vaccines in development

Immunogenicity of a DNA vaccine candidate for COVID-19

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2

Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: a phase 1, double-blind

Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine

Ebola vaccine trials: progress in vaccine safety and immunogenicity

Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial

Chimpanzee adenovirus vector Ebola vaccine

Recombinant vesicular stomatitis virus Ebola vaccine

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

Safety and Immunogenicity of two RNA-based Covid-19 vaccine candidates

Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

An mRNA vaccine against SARS-CoV-2 -preliminary report

Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults

Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers

Skeletal muscle cells: from local inflammatory response to active immunity

Cytokine gene expression in epidermis with biological effects following injection of naked DNA

Predominant role for directly transfected dendritic cells in antigen presentation to CD8 + T cells after gene gun immunization

Uptake and presentation of exogenous antigen and presentation of endogenously produced antigen by skin dendritic cells represent equivalent pathways for the priming of cellular immune responses following biolistic DNA immunization

CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes

West Nile virus: recent trends in diagnosis and vaccine development

Cancer immunology and canine malignant melanoma: a comparative review

First human trial of a DNAbased vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination

Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity

DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ Tcell responses after rAd5 boost in a randomized clinical trial

Improvements in cationic liposomes for in vivo gene transfer

Vaxfectin: a versatile adjuvant for plasmid DNA-and protein-based vaccines

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label

Food and Drug Administration (FDA) 2020. Development and Licensure of Vaccines to Prevent COVID-19; Guidance for Industry

Immunopathogenesis of coronavirus infections: implications for SARS

Prior immunization with severe acute respiratory syndrome (SARS) -associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV

A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge

Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus

M a n u s c r i p t 15 1 × 10 11